Form 4: Natera Director Gail Boxer Marcus Sells $650K in Company Stock Under Pre-Arranged 10b5-1 Plan

Natera, Inc. Director Gail Boxer Marcus executed a pre-planned sale of 4,000 shares of common stock totaling approximately $650,000 on June 10, 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Natera, Inc. Director Gail Boxer Marcus reported the sale of 4,000 shares of Natera common stock.
• The transactions occurred on June 10, 2025.
• A total of 3,400 shares were sold at a weighted average price of $164.3335 per share, with prices ranging from $164.00 to $164.99.
• An additional 600 shares were sold at a price of $165.045 per share.
• The total value of the shares sold is approximately $657,433.90.
• Following these transactions, Gail Boxer Marcus beneficially owns 5,704 shares of Natera common stock.
• The sales were conducted under a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which is a common practice for personal financial management and diversification, and does not necessarily reflect a negative view on the company's future prospects.

Positives

• The sale was executed pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to immediate company news, which can mitigate negative market perception of insider selling.

Negatives

• An insider sale, even if pre-planned, reduces the director's direct ownership stake in the company, which some investors might interpret as a lack of confidence, although this is often for personal financial planning or diversification.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market interpretation of insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Natera, Inc.'s future performance or outlook.

Management Comments

• The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not provide information relevant to broader industry trends or competitive dynamics within the diagnostics or biotechnology sectors.

Related Party Transactions

• The transaction involves a director of Natera, Inc. selling company stock, which is a common type of insider transaction.

Stakeholder Impact

• Shareholders: The sale by a director could be viewed with slight caution, but the 10b5-1 plan mitigates concerns about opportunistic selling. The impact on share price is likely minimal given the pre-planned nature and the volume relative to total shares outstanding.

Key Dates

Keywords

Natera, NTRA, Form 4, insider trading, stock sale, director, beneficial ownership, 10b5-1 plan, equity transaction